Overestimating the effects of healthy aging

Frontiers in Aging Neuroscience

Volumn 7, Issue AUG, 2015, Pages

  Kljajevic, Vanja ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Alzheimer's disease; Amyloidosis; Biomarkers; Cognitive aging; Neurodegeneration; Neuroimaging

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; ATTENTION; BEHAVIOR; BRAIN ATROPHY; COGNITION; DECISION MAKING; DEMENTIA; HUMAN; LANGUAGE; MEMORY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NOTE; SENILE PLAQUE;

EID: 84946552045     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2015.00164     Document Type: Note

References (14)

1. Bateman, R. (2015). Alzheimer's disease and other dementias: advances in 2014. Lancet Neurol. 14, 4-6. doi: 10.1016/S1474-4422(14)70301-1.
2. Brier, M. R., Thomas, J. B., Snyder, A. Z., Wang, L., Fagan, A. M., Benzinger, T., et al. (2014). Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging. Neurology 83, 1-7. doi:10.1212/WNL.0000000000000939.
3. Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., Dekosky, S. T., Barberger-Gateau, P., et al. (2010). Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9, 1118-1127. doi:10.1016/S1474-4422(10)70223-4.
4. Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., Cummings, J., et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734-746. doi:10.1016/S1474-4422(07)70178-3.
5. Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., et al. (2014). Advancing research diagnostic criteria for Alzheimer's disease: the IWG2 criteria. Lancet Neurol. 13, 614-629. doi:10.1016/S1474-4422(14)70090-0.
6. Gold, B. T., Johnson, N. F., and Powell, D. K. (2013). Lifelong bilingualism contributes to cognitive reserve against white matter integrity declines in aging. Neuropsychologia 51, 2841-2846. doi:10.1016/j.neuropsychologia.2013.09.037.
7. Harrison, T. M., Weintraub, S., Mesulam, M. M., and Rogalski, E. (2012). Superior memory and higher cortical volumes in unusually successful cognitive aging. J. Int. Neuropsychol. Soc. 18, 1081-1085. doi:10.1016/j.neuropsychologia.2013.09.037.
8. Jack, C. R. Jr, and Holtzman, D. M. (2013). Biomarker modeling of Alzheimer's disease. Neuron 80, 1347-1358. doi:10.1016/j.neuron.2013.12.003.
9. Jack, C. R. Jr, Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., et al. (2012). An operational approach to NIA-AA criteria for preclinical Alzheimer's disease. Ann. Neurol. 71, 765-775. doi:10.1002/ana.22628.
10. Jack, C. R. Jr, Wiste, H. J., Weigand, S. D., Rocca, W. A., Knopman, D. S., Mielke, M. M., et al. (2014). Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 13, 997-1005. doi:10.1016/S1474-4422(14)70194-2.
11. Riedel, W. J. (2014). Preventing cognitive decline in preclinical Alzheimer's disease. Curr. Opin. Pharmacol. 14, 18-22. doi:10.1016/j.coph.2013.10.002.
12. Rowe, J. H., and Kahn, R. L. (1987). Human aging: usual and successful. Science 237, 143-149. doi:10.1126/science.3299702.
13. Selkoe, D. J. (2012). Preventing Alzheimer's disease. Science 337, 1488-1492. doi:10.1126/science.1228541.
14. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292. doi:10.1016/j.jalz.2011.03.003.